chronic%20myeloid%20leukemia
CHRONIC MYELOID LEUKEMIA

Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

Introduction

  • Also known as chronic myelogenous, myelocytic, or chronic granulocytic leukemia
  • Has three phases: chronic, accelerated & blast
  • Median age at presentation is at >50 years old

Definition

  • A myeloid disorder associated with Philadelphia (Ph) chromosome t(9;22)(q34;q11), a fusion of the breakpoint cluster region (BCR) & Abelson murine leukemia (ABL1) genes

Signs and Symptoms

  • Systemic symptoms:
    • Anemia
    • Abdominal fullness
    • Abdominal pain that may present with left upper quadrant pain & early satiety
    • Bleeding episodes due to platelet dysfunction
    • Fatigue
    • Malaise
    • Weight loss
  • Other frequent findings:
    • Splenomegaly
    • Platelet count raised
    • White blood cell (WBC) count increased
    • Involvement of lymph nodes, skin & soft tissue (patients with blast crisis)

Risk Factors

  • The only known risk factor is exposure to ionizing radiation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course